TiGenix to present positive 52week Phase III results of Cx601 at World...
PRESS RELEASE TiGenix to present positive 52week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meetingÂÂ Â Leuven BELGIUM October 5 2017 0700h CET TiGenix NV Euronext...
View ArticleResults from Phase 2 Studies of Oral Ozanimod in Crohns Disease and...
In the STEPSTONE openlabel study ozanimod demonstrated meaningful clinical and endoscopic improvements in patients with moderately to severely active Crohns disease at week 12 In the TOUCHSTONE...
View ArticleComment Rapid changes in epidemiology of inflammatory bowel disease
The prevalence of inflammatory bowel disease that is Crohn's disease and ulcerative colitis has increased over two to three generations in highincome countries but in only one generation the past 25...
View ArticleScientific Update for Diabetes Kidney Ischemia Liver Perfusion Retinal Cell...
ProtoKinetix Incorporated www.protokinetix.com the "Company" or "ProtoKinetix" OTCQBPKTX is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for...
View ArticleBRIEFEntyvio analyses show improvements in ulcerative colitis or Crohns disease
Takeda Pharmaceutical has announced the presentation of data suggesting early symptomatic improvement
View ArticleGlobal Gastrointestinal Partnering 20102017 Deal trends players and...
Global Gastrointestinal Partnering 2010 to 2017 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends...
View ArticleNew analysis backs use of Takedas Entyvio
Takeda has presented data from a posthoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.
View ArticleProtagonist Therapeutics nets $56.4mm via FOPO
GIfocused Protagonist Therapeutics Inc. peptide therapies netted $56.4mm via a followon public offering of 3.53mm common shares priced at $17 each. The company plans to use the funds for ongoing...
View ArticleViaDerma Inc. Commences Distribution of VitaStemTM its FDA Registered Topical...
LOS ANGELES CAMarketwired October 19 2017 ViaDerma Inc. OTC PINK VDRM a specialty pharmaceutical company devoted to bringing new products to market recently announced today that the Company has begun...
View ArticlePhase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple...
Ozanimod highlighted in two oral presentations detailing results from phase III SUNBEAM and RADIANCE trials in RMS Additional clinical and nonclinical poster presentations will further characterize the...
View ArticleCelgene Provides Update on GED0301 mongersen Inflammatory Bowel Disease Program
Celgene Corporation NASDAQ CELG today announced that the GED0301 mongersen phase III REVOLVE trial CD002 in Crohns disease CD and the extension trial SUSTAIN CD004 will discontinue. Celgene has decided...
View ArticleCelgene Discontinues GED0301 Inflammatory Bowel Disease Program
SUMMIT N.J.&8211;BUSINESS WIRE&8211;Celgene Corporation NASDAQ CELG today announced that the GED0301 mongersen phase III REVOLVE trial CD002 in Crohns disease CD and the extension trial SUSTAIN...
View ArticleCelgene just lost a crucial drug for its revenue stream after a clinical...
Celgene just lost one of the most important drugs in its research pipeline a treatment for Crohn's disease to a latestage clinical trial blowup.
View ArticleCelgene abandons Crohn's drug trials shares drop
Reuters Celgene Corp said it would abandon testing a drug to treat Crohn's disease in a major setback to the U.S. biotechnology company's pipeline amid attempts to lower dependence on its mainstay...
View Article$710M Gamble Fails as Celgene Terminates Two Phase III Trials
Celgene is scrapping a latestage Crohn's disease drug it acquired in a $710M deal three years ago following an interim data analysis.
View ArticleCelgene to stop testing Crohn's drug shares drop
Celgene Corp said it would abandon testing a drug to treat Crohn&39;s disease in a major setback to the U.S. biotechnology company&39;s pipeline amid attempts to lower dependence on its...
View ArticleCelgene calls it quits on expensive Crohn's drug
The big biotech is discontinuing development of a potential blockbuster putting pressure on its pipeline product ozanimod to outperform.
View ArticleCelgene Down After Pulling Plug on Crohn's Disease Drug Study Biotech Movers
Click to view a price quote on CELG. Click to research the Drugs industry.
View Article